EMEA-001024-PIP01-10-M02
Key facts
| Invented name |
Nuwiq and associated names
|
| Active substance |
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0014/2020
|
| PIP number |
EMEA-001024-PIP01-10-M02
|
| Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
| Condition(s) / indication(s) |
Treatment of haemophilia A (congenital factor-VIII deficiency)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Octapharma Pharmazeutika Produktionsges.m.b.H
E-mail: sigurd.knaub@octapharma.ch |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001024-PIP01-10-M02
|
| Compliance opinion date |
26/03/2021
|
| Compliance outcome |
positive
|